| Secondary |
| Drug Use For Unknown Indication |
24.3% |
| Hypertension |
12.9% |
| Product Used For Unknown Indication |
11.1% |
| Atrial Fibrillation |
9.5% |
| Deep Vein Thrombosis |
4.3% |
| Essential Thrombocythaemia |
4.3% |
| Arrhythmia |
4.2% |
| Hiv Infection |
3.9% |
| Hypercholesterolaemia |
3.6% |
| Rheumatoid Arthritis |
2.7% |
| Urinary Tract Infection |
2.6% |
| Bronchitis |
2.5% |
| Type 2 Diabetes Mellitus |
2.5% |
| Dyslipidaemia |
1.9% |
| Small Cell Lung Cancer Stage Unspecified |
1.9% |
| Ischaemic Cardiomyopathy |
1.7% |
| Anaemia |
1.6% |
| Phlebitis |
1.6% |
| Depression |
1.4% |
| Hyperuricaemia |
1.4% |
|
| International Normalised Ratio Increased |
19.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
12.3% |
| Drug Interaction |
11.0% |
| Rectal Haemorrhage |
8.0% |
| Muscle Haemorrhage |
7.4% |
| Urethral Haemorrhage |
5.5% |
| Subdural Haematoma |
4.9% |
| Overdose |
4.3% |
| Drug Ineffective |
3.1% |
| Renal Failure Acute |
3.1% |
| Haemarthrosis |
2.5% |
| Oral Mucosa Erosion |
2.5% |
| Shock Haemorrhagic |
2.5% |
| Vomiting |
2.5% |
| Haematoma |
1.8% |
| Haemorrhage |
1.8% |
| International Normalised Ratio Decreased |
1.8% |
| Myositis |
1.8% |
| Pain |
1.8% |
| Pyrexia |
1.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
25.6% |
| Product Used For Unknown Indication |
20.8% |
| Hypertension |
10.4% |
| Atrial Fibrillation |
5.8% |
| Rheumatoid Arthritis |
5.1% |
| Type 2 Diabetes Mellitus |
5.0% |
| Cardiac Failure |
3.1% |
| Arrhythmia |
2.7% |
| Pulmonary Arterial Hypertension |
2.7% |
| Multiple Myeloma |
2.7% |
| Prophylaxis |
2.2% |
| Dyslipidaemia |
2.1% |
| Pain |
1.9% |
| Depression |
1.6% |
| Hypercholesterolaemia |
1.6% |
| Pulmonary Hypertension |
1.5% |
| Hiv Infection |
1.4% |
| Stent Placement |
1.3% |
| Thrombosis Prophylaxis |
1.3% |
| Arthralgia |
1.2% |
|
| Renal Failure Acute |
12.1% |
| Pyrexia |
6.1% |
| Sepsis |
6.1% |
| Somnolence |
6.1% |
| Spinal Osteoarthritis |
6.1% |
| Thrombocytopenia |
6.1% |
| Vomiting |
6.1% |
| Renal Failure |
5.5% |
| Vasculitis |
5.5% |
| Fall |
4.8% |
| Pulmonary Embolism |
4.2% |
| Toxic Skin Eruption |
4.2% |
| Tubulointerstitial Nephritis |
4.2% |
| Death |
3.6% |
| Rhabdomyolysis |
3.6% |
| Syncope |
3.6% |
| Atrial Fibrillation |
3.0% |
| Cardiac Failure |
3.0% |
| International Normalised Ratio Increased |
3.0% |
| Malaise |
3.0% |
|
| Interacting |
| Drug Use For Unknown Indication |
37.1% |
| Product Used For Unknown Indication |
11.4% |
| Hypertension |
9.0% |
| Generalised Oedema |
6.3% |
| Cardiac Failure Chronic |
3.9% |
| Bronchitis |
3.7% |
| Atrial Fibrillation |
3.5% |
| Hiv Infection |
3.1% |
| Pulmonary Embolism |
2.9% |
| Tuberculosis |
2.5% |
| Antibiotic Prophylaxis |
2.4% |
| Immunosuppression |
2.4% |
| Anticoagulant Therapy |
2.2% |
| Pain |
1.6% |
| Prostatic Adenoma |
1.6% |
| Sciatica |
1.6% |
| Thrombophlebitis |
1.6% |
| Bronchopneumonia |
1.2% |
| Superinfection |
1.2% |
| Depression |
1.0% |
|
| International Normalised Ratio Increased |
16.9% |
| Overdose |
13.5% |
| Tachypnoea |
11.2% |
| Drug Interaction |
9.0% |
| Rectal Haemorrhage |
6.7% |
| Haematuria |
4.5% |
| Haemorrhage |
4.5% |
| Pulmonary Embolism |
4.5% |
| Immunosuppressant Drug Level Decreased |
3.4% |
| Shock |
3.4% |
| Coagulation Time Shortened |
2.2% |
| Epistaxis |
2.2% |
| Gastric Ulcer Haemorrhage |
2.2% |
| International Normalised Ratio Decreased |
2.2% |
| Muscle Haemorrhage |
2.2% |
| Oesophageal Ulcer |
2.2% |
| Prothrombin Level Increased |
2.2% |
| Scar |
2.2% |
| Subdural Haematoma |
2.2% |
| Weight Decreased |
2.2% |
|
